Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
IMvigor210
Description:
IMvigor210 is a clinical study of atezolizumab treatment in patients with advanced or metastatic urothelial carcinoma.
Primary topic:
Cancer Immunotherapy and Biomarkers (43%)
Related topics:
Cancer Immunotherapy and Biomarkers (43%),
Bladder and Urothelial Cancer Treatments (29%)
OpenAlex ID:
keywords/imvigor210
Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures
2019
·
Dongqiang Zeng
, Meiyi Li
, et al.
·
Cancer Immunology Research
·
1,227
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
2017
·
A. Necchi
, R.W. Joseph
, et al.
·
Annals of Oncology
·
336
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
2018
·
Daniel L. Suzman
, Sundeep Agrawal
, et al.
·
The Oncologist
·
206
PDF
ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
2020
·
Sangeeta Goswami
, Yulong Chen
, et al.
·
Science Translational Medicine
·
138
Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
2020
·
Ashley M. Hopkins
, Ganessan Kichenadasse
, et al.
·
European Urology
·
114
Identification and quantification of immune infiltration landscape on therapy and prognosis in left- and right-sided colon cancer
2021
·
Jun-Nan Guo
, Du Chen
, et al.
·
Cancer Immunology Immunotherapy
·
85
PDF
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
2023
·
Kazumasa Komura
, Kensuke Hirosuna
, et al.
·
Molecular Cancer
·
67
PDF
Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer
2021
·
Mengmeng Sun
, Han Zeng
, et al.
·
Cancer Immunology Immunotherapy
·
52
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens
2017
·
Jose Luis Perez-Gracia
, Yohann Loriot
, et al.
·
European Urology
·
51
Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment
2023
·
Yuxuan Song
, Yun Peng
, et al.
·
Journal for ImmunoTherapy of Cancer
·
49
PDF
PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210).
2016
·
Jonathan E. Rosenberg
, Daniel Peter Petrylak
, et al.
·
Journal of Clinical Oncology
·
45
Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
2020
·
Tae Jin Kim
, Kang Su Cho
, et al.
·
Cancers
·
44
PDF
LRP1 induces anti-PD-1 resistance by modulating the DLL4-NOTCH2-CCL2 axis and redirecting M2-like macrophage polarisation in bladder cancer
2024
·
Hansen Lin
, Liangmin Fu
, et al.
·
Cancer Letters
·
40
Metabolic reprogramming involves in transition of activated/resting CD4+ memory T cells and prognosis of gastric cancer
2023
·
Yue Sun
, Li Liu
, et al.
·
Frontiers in Immunology
·
39
PDF
M7G-related molecular subtypes can predict the prognosis and correlate with immunotherapy and chemotherapy responses in bladder cancer patients
2023
·
Deng-xiong Li
, De-chao Feng
, et al.
·
European journal of medical research
·
38
PDF
Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.
2018
·
Arjun Vasant Balar
, Robert Dreicer
, et al.
·
Journal of Clinical Oncology
·
38
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
2016
·
Arjun Vasant Balar
, Matt D. Galsky
, et al.
·
Journal of Clinical Oncology
·
36
Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
2021
·
Ahmad Y. Abuhelwa
, Ganessan Kichenadasse
, et al.
·
Cancers
·
34
PDF
M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer
2021
·
Zhou JiaWei
, Dou ChunXia
, et al.
·
Annals of Medicine
·
34
Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy
2021
·
Ahmad Y. Abuhelwa
, Joaquim Bellmunt
, et al.
·
Clinical Genitourinary Cancer
·
31
Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
2020
·
Xianghong Zhou
, Shi Qiu
, et al.
·
Frontiers in Oncology
·
31
PDF
Epigenetic and Tumor Microenvironment for Prognosis of Patients with Gastric Cancer
2023
·
Zenghong Wu
, Weijun Wang
, et al.
·
Biomolecules
·
30
PDF
Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
2022
·
Rui Yang
, Wengang Zhang
, et al.
·
Frontiers in Pharmacology
·
30
IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
2018
·
Matt D. Galsky
, Enrique Grande
, et al.
·
Journal of Clinical Oncology
·
29
Systematic identification, development, and validation of prognostic biomarkers involving the tumor‐immune microenvironment for glioblastoma
2020
·
Binghao Zhao
, Yuekun Wang
, et al.
·
Journal of Cellular Physiology
·
28
Show more works
View as search
Works count:
241
Citation count:
3,700
Year
Topic
Type